Compare Ishares Msci Spain ETF (EWP) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ishares Msci Spain ETF vs Novartis AG — how do they compare? Ishares Msci Spain ETF trades at $62.65, while Novartis AG trades at $154.71 (market cap $298.18B). The key difference: Novartis AG pays a 3.02% dividend while Ishares Msci Spain ETF pays none, and Ishares Msci Spain ETF is trading nearer its 52-week high, Novartis AG nearer its low. Which is the better fit depends on your goals.
| EWP | NVS | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $62.66 | $168.62 |
52-Week Low | $47.02 | $119.31 |
Market Cap | — | $298.18B |
Enterprise Value | — | $339.50B |
Dividend Yield | — | 3.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWP is trading at $62.66, up 0.58% with a bullish technical signal driven by strong moving average support. The stock shows mixed momentum with overbought RSI readings but positive ADX trend strength. Recent corporate actions include a $0.92 dividend scheduled for June 2026. European market sentiment remains influenced by ECB policy decisions and energy price volatility.
The stock's outlook balances technical strength against fundamental data gaps. European economic resilience and potential short-squeeze dynamics offer upside, while overbought conditions and geopolitical risks present near-term headwinds. Dividend income provides additional shareholder value, though comprehensive financial metrics are needed for full fundamental assessment.
Novartis (NVS) trades at $156.33, up 1.37% on the day, with a bullish technical signal and strong support near $156. The company reported Q2 2026 earnings that beat expectations, driven by robust oncology drug sales, and reaffirmed full-year guidance. Revenue for 2025 was $56.67 billion with a net income margin of 22.5%, while valuation ratios like P/E of 23.61 and P/B of 7.15 reflect premium pricing. Recent news highlights institutional buying and CEO confidence in the growth pipeline.
The outlook for NVS is positive, supported by earnings momentum and a diversified drug portfolio, but risks include generic competition for Entresto and pricing pressures. Analyst consensus is mixed with 24% buy ratings, indicating cautious optimism. Investment appeal hinges on execution of new drug launches and offsetting legacy product declines.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ishares Msci Spain ETF
EWP is a country-specific ETF that tracks the performance of the Spanish equity market. It provides targeted access to large and mid-sized companies in Spain, with heavy weightings in financials and utilities like Banco Santander and Iberdrola.
Read more on EWP →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
